News

Regulator finds advertising of complementary product “misleading”

BMJ 2006; 333 doi: 10.1136/bmj.39044.539097.DB (Published 30 November 2006)
Cite this as: BMJ 2006;333:1141.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Bob Burton
  1. 1Canberra

    The Australian regulator of the drug industry has found that the company Schwabe Pharma (Australia) breached standards for media advertisements when it promoted the complementary medicine Tebonin.

    Tebonin, which is an extract of ginkgo biloba, is manufactured by the German company Dr Willmar Schwabe, which claims that eight million Tebonin pills are consumed globally each day.

    In July, the company's Australian subsidiary managed to suppress publication of a report by AusPharm Consumers Health Watch, a …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular